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Abstract
Purpose To examine the potential high throughput
capability and eYciency of an automated DNA extraction
system in combination with mass spectrometry for the non-
invasive determination of the foetal Rhesus D status.
Methods A total of 178 maternal plasma samples from
RHD-negative pregnant women were examined, from
which DNA was extracted using the automated Roche
MagNA Pure™ system. Presence of the foetal RHD gene
was detected by PCR for RHD exon 7 and subsequent anal-
ysis using the Sequenom MassArray™ mass spectrometric
system.
Results We determined that as little as 15 pg of RHD-pos-
itive genomic DNA could be detected in a background of
585 pg of RHD-negative genomic DNA. The analysis of
the clinical samples yielded a sensitivity and speciWcity
of 96.1 and 96.1%, respectively.
Conclusion Our study indicated that automated DNA
extraction in combination with mass spectrometry permits
the determination of foetal Rhesus D genotype with an
accuracy comparable to the current approaches using real-
time PCR.
Keywords Rhesus D · RHD · MALDI-TOF · 
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Introduction
The non-invasive determination of the foetal RHD status
via the analysis of cell-free foetal DNA in maternal
plasma or serum by real-time PCR is well established and
already oVered as a clinical service in a number of coun-
tries [2, 6]. This development can greatly assist with the
screening and monitoring of pregnancies at risk for hae-
molytic disease of the foetus and newborn (HDN), and
also reduce the health care costs by avoiding unnecessary
prophylactic treatment in those cases where the foetus is
RHD negative [7].
It has recently been shown that MALDI-TOF (matrix
assisted laser desorption ionization-time of Xight) mass
spectrometric devices, such as the Sequenom MassArray™
system, can be used for the detection of foetal genetic loci
by the analysis of cell-free foetal DNA in maternal plasma
or serum [11, 12]. The main advantage of this approach
over conventional real-time PCR is that it permits the ready
detection of foetal genetic loci which only diVer slightly
from the maternal counterpart, such as point mutations.
Furthermore, it is possible to examine a large number of
multiplex PCR products by mass spectrometry, implying
that a large number of mutations or diVerent loci can be
examined in a single analysis [18]. A further attribute of the
MassArray™ system is that it is highly amenable to high
throughput analysis of several thousand samples per day.
Consequently, it has been proposed that this system may be
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clinical diagnostic labs [5, 11, 12].
As to date few large-scale studies have examined the
suitability of such a system for this purpose, we have now
performed a study in which 178 clinical samples were ana-
lysed in a blinded manner for the presence or absence of the
foetal RHD gene.
Materials and methods
Plasma sample collection and processing
The study was approved by the review boards from both the
institutions. After written informed consent, 15 mL EDTA
blood samples were obtained from pregnant women at risk
for HDN caused by alloimmunization. The samples were
processed on site at the University of Göttingen, Germany,
by twofold centrifugation (1: 10 min, 2,700£g; 2: 45 min
12,500£g). The plasma was divided into 1 mL aliquots and
stored at ¡80°C. One aliquot of each sample was frozen
and sent to Basel for analysis.
DNA isolation from maternal plasma
The automatic DNA isolation system MagNA Pure™
instrument (Roche Applied Science, Switzerland) was used
for plasma DNA extraction. Following the “DNA LV
Blood_1000.blk” protocol, DNA was extracted from 1 mL
of RHD-negative maternal plasma with the Roche MagNA
Pure™ Pure LC DNA Isolation Kit-Large Volume. The
DNA was eluted into 200 L of elution buVer and stored at
¡20°C for later use. A sample volume of 50 L was avail-
able for analysis.
Assay design
The assay design was kindly provided by Sequenom Inc.,
USA. As only the foetal RHD gene is detected, and no cor-
responding maternal allele, a SABER (single allele base
extension reaction) assay was used which exclusively
detects the presence of the RHD 7 exon (see below). All
oligonucleotides were synthesised and HPLC puriWed by
Microsynth (Switzerland). AmpliWcation primers contained
a 5–10 mer tag to keep them out of the analytical mass
range.
PCR ampliWcation
PCR reactions were performed in a total volume of 12.5 L
containing 8 L of eluted cfDNA, 400 nM of each primer
(PCR-RHD7-fw and PCR-RHD7-rev, Table 1), 3 mM Mg2+,
0.5 U HotStart Taq DNA Polymerase (Qiagen, Switzer-
land), 50 M dNTPs and 1£ PCR buVer. Thermal cycling
was performed as follows: 15 min at 95°C followed by 50
cycles of 95°C for 45 s, 57°C for 45 s and 72°C for 1 min.
The reaction was completed with a Wnal extension at 72°C
for 7 min.
Shrimp alkaline phosphatase (SAP) treatment
For the dephosphorylation of excess dNTPs, 4 L of a solu-
tion containing 3.06 L ddH2O, 0.34 L hME buVer
(Sequenom Inc.) and 0.6 L shrimp alkaline phosphatase
(Sequenom Inc.) were added to 12.5 L of PCR product.
After incubation at 37°C for 60 min, the enzyme was inacti-
vated at 85°C for 5 min.
Single allele base extension reaction
Four microliters of a solution containing 3.12 L ddH2O,
0.4 L Termination Mix C (containing 2,3-dideoxycytos-
intriphosphate (ddCTP), Sequenom Inc.), 0.4 L 25 M
RHD7 extension primer (Table 1) and 0.08 L (2.56 U)
Thermo Sequenase (Sequenom Inc.) were added to 18.5 L
SAP treated PCR product. Thermal cycling was performed
as follows: 2 min at 94°C followed by 99 cycles of 94°C for
5 s, 51°C for 5 s and 52°C for 5 s.
Desalting and mass spectrometric analysis
A total of 29.5 L H2O and 6 mg of SpectroCLEAN resin
(Sequenom Inc.) were added to 20.5 L extension product.
The plate was rotated for 10 min at room temperature fol-
lowed by centrifugation at 3,000£g for 3 min to pellet the
resin.
A total of 15 nL of each desalted sample were dispensed
onto a 384-format SpectroCHIP using a MassARRAY
Table 1 Oligonucleotides for 
PCR and extension reaction and 
corresponding masses used for 
the RHD exon 7 mass 
spectrometry assay
PCR-RHD7-fw 5-ACGTTGGATGGGGTGTTGTAACCGAGTGCTG-3
PCR-RHD7-rev 5-ACGTTGGATGCCGGCTCCGACGGTATC-3
RHD7 extension primer 5-ATTCCCCACAGCTCCAT-3
SABER-assay terminator 2,3-dideoxycytosintriphosphate (ddCTP)
Mass of extension primer 5050.3 Da
Mass of extension product 
(Call: G)
5323.5 Da123
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by MassARRAY Analyzer Compact. The data were
recorded and interpreted by MassARRAY TYPER (Seque-
nom Inc.) software.
Results
Validation of the mass spectrometry Assay for RHD exon 7
To evaluate the sensitivity of the SABER assay, we serially
diluted RHD-positive genomic DNA into RHD-negative
genomic DNA, such that the overall quantity of DNA was
600 pg per reaction. This is the equivalent amount to that
normally present in cell-free DNA preparations. Under
these conditions, we were able to detect 15 pg of RHD-positive
genomic DNA in a background of 585 pg of RHD-negative
genomic DNA (Fig. 1). This is almost equal to the three
copies of the RHD gene in a single reaction, indicating that
the RHD assay exhibits a degree of sensitivity and speciWc-
ity suitable for the analysis of cell-free foetal DNA.
Detection of the foetal RHD exon 7 in maternal plasma
A total of 178 samples were analysed in a blinded manner.
The results were conWrmed by those obtained from serolog-
ical analysis using cord blood in Göttingen. The presence
or absence of the foetal RHD exon 7 was determined fol-
lowing the analysis of the samples in duplicates. If the
result was unambiguously positive or negative, the samples
were scored accordingly. If the result was equivocal, the
sample was re-analysed in duplicate. The sample was only
Fig. 1 Sensitivity and speciWcity of the RHD assay using the MALDI-
TOF MS based SABER approach. RHD-positive genomic DNA was
diluted into RHD-negative genomic DNA. The total DNA amount per
reaction was 600 pg. a 600 pg RHD-positive genomic DNA. b 30 pg
RHD-positive DNA in 570 pg RHD-negative background. c 15 pg
RHD-positive DNA in 585 pg RHD-negative background. d 600 pg
RHD negative genomic DNA. UEP unextended primer, G RHD allele,
PP pausing peak123
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detected amongst the two sets of duplicates, else it was
scored as RHD negative.
Following a comparison of our results with those
obtained by classical serology of the cord blood, we ascer-
tained that out of 178 samples we had examined, Wve sam-
ples had been incorrectly scored as RHD negative and two
samples incorrectly determined as being RHD positive
(Table 2). This equates to a sensitivity of 96.1% and a spec-
iWcity of 96.1%. Our data show 96.1% concordance to
those obtained by quantitative real-time PCR.
Discussion
Non-invasive prenatal RHD analysis is currently most fre-
quently performed using real-time PCR, either in conjunc-
tion with manual or automated procedures for the
extraction of cell-free DNA from the maternal plasma/
serum samples [4, 9, 13, 15, 16, 19]. In this study, we
analysed the foetal RHD status by mass spectrometry, in
combination with automated system for the extraction of
cell-free DNA from maternal plasma.
The validation of the assay showed that we were able to
detect as little as 2.5% of RHD-positive genomic DNA in a
background of RHD-negative genomic DNA, indicating
that the assay is very sensitive. A similar sensitivity (20 pg
mutant DNA in 580 pg wildtype DNA) has recently been
reported by our group for the mass spectrometry based
genotyping of the foetal KEL1 blood group from cell-free
DNA in maternal plasma [11].
Out of 178 samples, Wve cases were incorrectly scored as
RHD negative and two were incorrectly scored as RHD
positive. Of those Wve false negative samples, three were
obtained during the third trimester, while the remaining two
were from the second trimester of pregnancy. The two sam-
ples that were scored false positive were from the second
and third trimester or pregnancy. These remained to be
assessed incorrectly, even after several rounds of re-analy-
sis, indicating that the sample may have been contaminated.
As the samples stem from a Caucasian population, a false
positive result caused by the inactive allele RHD [10, 16]
is unlikely, but can only be excluded convincingly by
examining for the presence of this allele.
In those cases where the foetal RHD gene cannot be
detected, it is unclear, whether the foetus is Rhesus-nega-
tive or if the amount of foetal DNA in the sample is below
the detection limit of the system. For the exclusion of the
latter case, the detection of paternally inherited single
nucleotide polymorphisms [12], the detection of a Y-chro-
mosome speciWc sequence [8], or the detection of an epige-
netic marker such as the foetal hypermethylated RASSF1A
sequence [3] can be performed. In our current study, we
were unable to perform such additional analyses due to
very limited amount of sample available.
A recent review of large-scale studies reporting on the
non-invasive determination of foetal RHD status by the
real-time PCR analysis of cell-free DNA indicated that
accuracies between 95 and 99% could be attained [14]. As
such, our data yielding an overall accuracy of 96.1% concur
favourably with those obtained by real-time PCR.
In future studies we aim to make better use of the Seque-
nom MassArray™ mass spectrometric system, by perform-
ing multiplex analyses. In this manner it will be possible to
detect variant RHD alleles such as the RHD gene [1, 17],
as well as polymorphic markers indicating whether cell-
free foetal DNA was present in the sample or not. This
added information will increase the value of the analysis,
and by being able to perform these numerous examinations
in a single analytic run, help to reduce costs.
In this manner, the combination of an automated DNA
extraction system and mass spectrometry may emerge as a
competitive alternative to the current commonly used real-
time PCR approaches used to determine non-invasively the
foetal RHD status.
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